Summit Therapeutics heads into its May 4 Q1 print riding a sharp reversal — up 26% in a month — while options traders quietly lean more bullish than at almost any point this year.
The clearest positioning signal is in the options market, where the put/call ratio has drifted to 0.62 — below its 20-day average of 0.65 and approaching its 52-week low of 0.50. That tilt reflects growing call demand relative to puts, the mirror image of what a defensive posture looks like. Borrow conditions reinforce the picture: cost to borrow is running at just 0.92% annually, down roughly 11% over the past week and 14% over the past month, suggesting no squeeze dynamic is building. Availability in the lending market remains moderate, with roughly 39% of borrowed shares still available for new shorts — loose enough that there is no shortage of supply. Short interest at 4.3% of the free float is not trivial, but it has been declining steadily, down over 8% in the past month.
The debate on SMMT centres almost entirely on ivonescimab, the bispecific antibody licensed from Akeso. Bulls point to the drug's potential in non-small cell lung cancer and broader solid tumours, and the EPS surprise track record here is exceptional — ranking in the 98th percentile across the universe, a signal that management has consistently outrun consensus expectations. Stifel initiated with a Buy and a $45 target in early April, well above where the stock now trades. The ORTEX short score of 81 places Summit among the more scrutinised names in biotech, but the analyst recommendation divergence score ranks in the 91st percentile, meaning the Street is more divided on the name than almost any other stock. Bears focus on the single-asset risk: ivonescimab or nothing, and Jefferies captured that view by cutting to Hold and slashing its target from $42 to $15 in mid-March. That target now looks below current levels, but it underscores how binary the risk profile is.
Ownership data tells a genuinely unusual story. Chairman and CEO Robert Duggan controls 73.5% of shares outstanding — a concentration that leaves public float extraordinarily thin relative to total shares. Akeso itself holds a further 4.1%. On the institutional side, T. Rowe Price and FMR (Fidelity) both meaningfully added to positions in their most recent filings, each growing by over 4 million shares. The stock's closest correlated peers have had a difficult week — ARTV fell 26% and CRBU lost 19% over the same period — while SMMT managed only a 3.6% decline, a relative hold that underscores the stock's idiosyncratic, catalyst-driven character.
The May 4 print is less a traditional financial exercise and more a trial-data proxy: what management says about ivonescimab development timelines, partnership dynamics with Akeso, and the path to Phase 3 data will test whether the 26% one-month rally reflects genuine clinical optimism or has run ahead of what the company can actually deliver.
See the live data behind this article on ORTEX.
Open SMMT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
